FDA Brief

Warning letters Drugs

FDA warning letter to

Zenzi Pharmaceutical Industries Pvt. Ltd.

High riskIssued Feb 13, 2025Posted Feb 18, 2025Center for Drug Evaluation and Research (CDER)

Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

What happened

FDA reviewed records and sent an electronic request on October 29, 2024, to the contact email in the customer’s contract manufacturing agreement; it went unanswered. Follow-up requests were sent November 7 and November 15, 2024. The company’s Vice President of Quality replied November 13 denying it supplied the product, contradicting customer records, and the company did not provide the requested records.

What FDA found

  1. The company did not provide records FDA requested under section 704(a)(4) about drugs made at the facility.

    FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)
  2. The company did not answer FDA’s follow-up written requests dated November 7 and November 15, 2024.

    FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)
  3. Refusing to permit access to or copying of required records is a prohibited act.

    FD&C Act section 301(e), 21 U.S.C. 331(e)

What FDA wants

Respond in writing within 15 working days, identifying FEI 3032916295 and ATTN: Kevin Maguire; the company may provide information or request an FDA inspection.

Who should pay attention

  • U.S. drug buyers and distributors sourcing from this contract manufacturer
  • brands that use Zenzi as a contract manufacturer
  • quality teams tracking supplier import alerts and records requests

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  3. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium
  4. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk